231 related articles for article (PubMed ID: 30219771)
1. Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus.
Peschken CA; Wang Y; Abrahamowicz M; Pope J; Silverman E; Sayani A; Iczkovitz S; Ross J; Zummer M; Tucker L; Pineau C; Levy D; Hudson M; Hitchon CA; Huber AM; Smith CD; Avina-Zubieta A; Arbillaga H; Chédeville G; Wynant W; Fortin PR;
J Rheumatol; 2019 Feb; 46(2):166-175. PubMed ID: 30219771
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
[TBL] [Abstract][Full Text] [Related]
3. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus disease activity index 2000.
Gladman DD; Ibañez D; Urowitz MB
J Rheumatol; 2002 Feb; 29(2):288-91. PubMed ID: 11838846
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177
[TBL] [Abstract][Full Text] [Related]
6. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients.
Jesus D; Rodrigues M; Matos A; Henriques C; Pereira da Silva JA; Inês LS
Lupus; 2019 Apr; 28(5):607-612. PubMed ID: 30895904
[TBL] [Abstract][Full Text] [Related]
7. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort.
Watson P; Brennan A; Birch H; Fang H; Petri M
Rheumatology (Oxford); 2015 Apr; 54(4):623-32. PubMed ID: 25234659
[TBL] [Abstract][Full Text] [Related]
8. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.
Jesus D; Matos A; Henriques C; Zen M; Larosa M; Iaccarino L; Da Silva JAP; Doria A; Inês LS
Ann Rheum Dis; 2019 Mar; 78(3):365-371. PubMed ID: 30626657
[TBL] [Abstract][Full Text] [Related]
9. Summarizing disease features over time: II. Variability measures of SLEDAI-2K.
Ibañez D; Gladman D; Urowitz M
J Rheumatol; 2007 Feb; 34(2):336-40. PubMed ID: 17183620
[TBL] [Abstract][Full Text] [Related]
10. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months.
Touma Z; Urowitz MB; Taghavi-Zadeh S; Ibañez D; Gladman DD
Rheumatology (Oxford); 2012 Oct; 51(10):1814-9. PubMed ID: 22718868
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
[TBL] [Abstract][Full Text] [Related]
13. Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores.
Speyer CB; Li D; Guan H; Yoshida K; Stevens E; Jorge AM; Everett BM; Feldman CH; Costenbader KH
Rheumatol Int; 2020 Feb; 40(2):257-261. PubMed ID: 31784790
[TBL] [Abstract][Full Text] [Related]
14. Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.
Urowitz MB; Gladman DD; Ibañez D; Su J; Mursleen S; Sayani A; Ross Terres JA; Iczkovitz S
J Rheumatol; 2021 Jan; 48(1):67-73. PubMed ID: 32238510
[TBL] [Abstract][Full Text] [Related]
15. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.
Urowitz MB; Gladman DD; Ibañez D; Fortin PR; Bae SC; Gordon C; Clarke A; Bernatsky S; Hanly JG; Isenberg D; Rahman A; Sanchez-Guerrero J; Wallace DJ; Ginzler E; Alarcón GS; Merrill JT; Bruce IN; Sturfelt G; Nived O; Steinsson K; Khamashta M; Petri M; Manzi S; Ramsey-Goldman R; Dooley MA; van Vollenhoven RF; Ramos M; Stoll T; Zoma A; Kalunian K; Aranow C
Arthritis Care Res (Hoboken); 2012 Jan; 64(1):132-7. PubMed ID: 21954226
[TBL] [Abstract][Full Text] [Related]
16. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
[TBL] [Abstract][Full Text] [Related]
17. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
[TBL] [Abstract][Full Text] [Related]
18. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
[TBL] [Abstract][Full Text] [Related]
19. Defining Low Disease Activity in Systemic Lupus Erythematosus.
Polachek A; Gladman DD; Su J; Urowitz MB
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):997-1003. PubMed ID: 27696791
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of hospital admissions with active systemic lupus erythematosus disease activity defined by two different disease activity indices: A cohort study.
Wang CL; Koo M; Hsu CW; Lu MC
Lupus; 2023 Jun; 32(7):864-872. PubMed ID: 37165549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
